100 years of the Bacillus Calmette-Guérin vaccine.
作者信息
Bettencourt Paulo J G, Joosten Simone A, Lindestam Arlehamn Cecilia S, Behr Marcel A, Locht Camille, Neyrolles Olivier
机构信息
Catholic University of Portugal, Lisbon, Portugal; Centre for Interdisciplinary Research in Health, Catholic University of Portugal, Lisbon, Portugal.
Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.
出版信息
Vaccine. 2021 Dec 8;39(50):7221-7222. doi: 10.1016/j.vaccine.2021.11.038. Epub 2021 Nov 22.
Abstract
摘要
相似文献
1
100 years of the Bacillus Calmette-Guérin vaccine.
Vaccine. 2021 Dec 8;39(50):7221-7222. doi: 10.1016/j.vaccine.2021.11.038. Epub 2021 Nov 22.
2
Predictive biomarkers of response to bacillus Calmette-Guérin immunotherapy and bacillus Calmette-Guérin failure for non-muscle invasive bladder cancer.
Int J Urol. 2022 Aug;29(8):807-815. doi: 10.1111/iju.14921. Epub 2022 May 22.
3
History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.
J Urol. 2008 Jan;179(1):53-6. doi: 10.1016/j.juro.2007.08.122. Epub 2007 Nov 13.
4
Contributors to HMGB1 release by urothelial carcinoma cells in response to bacillus Calmette-Guérin.
J Urol. 2013 Oct;190(4):1398-403. doi: 10.1016/j.juro.2013.03.123. Epub 2013 Apr 11.
5
Granulomas of the penis: a rare complication of intravesical therapy with Bacillus Calmette-Guerin.
An Bras Dermatol. 2011 Jul-Aug;86(4):759-62. doi: 10.1590/s0365-05962011000400021.
6
Contemporary Outcomes of Patients with Nonmuscle-Invasive Bladder Cancer Treated with bacillus Calmette-Guérin: Implications for Clinical Trial Design.
J Urol. 2021 Jun;205(6):1612-1621. doi: 10.1097/JU.0000000000001633. Epub 2021 Jan 27.
7
Adverse reactions related to treatment compliance during BCG maintenance therapy for non-muscle-invasive bladder cancer.
Jpn J Clin Oncol. 2013 Aug;43(8):827-34. doi: 10.1093/jjco/hyt086. Epub 2013 Jul 14.
8
Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer.
Urol Oncol. 2021 Feb;39(2):121-129. doi: 10.1016/j.urolonc.2020.09.031. Epub 2020 Nov 28.
9
Bacillus Calmette-Guerin Vaccine and Nonspecific Immunity.
Am J Med Sci. 2021 Jun;361(6):683-689. doi: 10.1016/j.amjms.2021.03.003. Epub 2021 Mar 8.
10
Efficacy of bacillus Calmette-Guérin Strains for Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Network Meta-Analysis.
J Urol. 2017 Sep;198(3):503-510. doi: 10.1016/j.juro.2017.01.086. Epub 2017 Mar 10.
引用本文的文献
1
Integrative immune analysis in patients with leprosy reveals host factors associated with mycobacterial control.
EBioMedicine. 2025 Jul 18;118:105855. doi: 10.1016/j.ebiom.2025.105855.
2
Vaccines and Dementia: Part I. Non-Specific Immune Boosting with BCG: History, Ligands, and Receptors.
J Alzheimers Dis. 2024;98(2):343-360. doi: 10.3233/JAD-231315.
3
Beyond schistosomiasis: unraveling co-infections and altered immunity.
Clin Microbiol Rev. 2024 Mar 14;37(1):e0009823. doi: 10.1128/cmr.00098-23. Epub 2024 Feb 6.
4
BCG vaccination-induced acquired control of mycobacterial growth differs from growth control preexisting to BCG vaccination.
Nat Commun. 2024 Jan 2;15(1):114. doi: 10.1038/s41467-023-44252-5.
5
mRNA vaccines: a new opportunity for malaria, tuberculosis and HIV.
Front Immunol. 2023 Apr 24;14:1172691. doi: 10.3389/fimmu.2023.1172691. eCollection 2023.
6
Microbial Antigen Identification and Vaccine Delivery Systems.
Vaccines (Basel). 2022 Nov 30;10(12):2053. doi: 10.3390/vaccines10122053.
7
Evaluation of early innate and adaptive immune responses to the TB vaccine Mycobacterium bovis BCG and vaccine candidate BCGΔBCG1419c.
Sci Rep. 2022 Jul 20;12(1):12377. doi: 10.1038/s41598-022-14935-y.
8
Recombinant BCG to Enhance Its Immunomodulatory Activities.
Vaccines (Basel). 2022 May 23;10(5):827. doi: 10.3390/vaccines10050827.
9
Is the BCG Vaccine an Answer to Future Pandemic Preparedness?
Vaccines (Basel). 2022 Jan 27;10(2):201. doi: 10.3390/vaccines10020201.
本文引用的文献
1
BCG versus rBCG: What is the way forward?
Vaccine. 2021 Dec 8;39(50):7319-7320. doi: 10.1016/j.vaccine.2021.10.052.
2
Donor Unrestricted T Cells: Linking innate and adaptive immunity.
Vaccine. 2021 Dec 8;39(50):7295-7299. doi: 10.1016/j.vaccine.2021.10.044. Epub 2021 Nov 2.
3
BCG-induced immunity profiles in household contacts of leprosy patients differentiate between protection and disease.
Vaccine. 2021 Dec 8;39(50):7230-7237. doi: 10.1016/j.vaccine.2021.10.027. Epub 2021 Oct 20.
4
Effects of Mycobacterium bovis Calmette et Guérin (BCG) in oncotherapy: Bladder cancer and beyond.
Vaccine. 2021 Dec 8;39(50):7332-7340. doi: 10.1016/j.vaccine.2021.09.053. Epub 2021 Oct 7.
5
Weaker protection against tuberculosis in BCG-vaccinated male 129 S2 mice compared to females.
Vaccine. 2021 Dec 8;39(50):7253-7264. doi: 10.1016/j.vaccine.2021.09.039. Epub 2021 Sep 30.
6
Recombinant BCGs for tuberculosis and bladder cancer.
Vaccine. 2021 Dec 8;39(50):7321-7331. doi: 10.1016/j.vaccine.2021.09.040. Epub 2021 Sep 27.
7
Meeting report: Virtual Global Forum on Tuberculosis Vaccines, 20-22 April 2021.
Vaccine. 2021 Dec 8;39(50):7223-7229. doi: 10.1016/j.vaccine.2021.08.094. Epub 2021 Sep 15.
8
Does BCG provide long-term protection against SARS-CoV-2 infection? A case-control study in Quebec, Canada.
Vaccine. 2021 Dec 8;39(50):7300-7307. doi: 10.1016/j.vaccine.2021.08.019. Epub 2021 Aug 11.
9
ESX-5-targeted export of ESAT-6 in BCG combines enhanced immunogenicity & efficacy against murine tuberculosis with low virulence and reduced persistence.
Vaccine. 2021 Dec 8;39(50):7265-7276. doi: 10.1016/j.vaccine.2021.08.030. Epub 2021 Aug 19.
10
BCG for the prevention and treatment of allergic asthma.
Vaccine. 2021 Dec 8;39(50):7341-7352. doi: 10.1016/j.vaccine.2021.07.092. Epub 2021 Aug 18.
Zotero 插件